These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 14700452)

  • 1. Improving antidepressant adherence.
    Nemeroff CB
    J Clin Psychiatry; 2003; 64 Suppl 18():25-30. PubMed ID: 14700452
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immediate-release versus controlled-release formulations: pharmacokinetics of newer antidepressants in relation to nausea.
    DeVane CL
    J Clin Psychiatry; 2003; 64 Suppl 18():14-9. PubMed ID: 14700450
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Eight-week, placebo-controlled, double-blind comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR.
    Hewett K; Chrzanowski W; Schmitz M; Savela A; Milanova V; Gee M; Krishen A; Millen L; Leary MO; Modell J
    J Psychopharmacol; 2009 Jul; 23(5):531-8. PubMed ID: 18635695
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and tolerability of controlled-release paroxetine.
    Golden RN
    Psychopharmacol Bull; 2003; 37 Suppl 1():176-86. PubMed ID: 14566210
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bupropion extended-release for depressive disorders.
    Jefferson JW
    Expert Rev Neurother; 2008 May; 8(5):715-22. PubMed ID: 18457528
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bupropion sustained release: side effect profile.
    Settle EC
    J Clin Psychiatry; 1998; 59 Suppl 4():32-6. PubMed ID: 9554319
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The treatment of depression with different formulations of venlafaxine: a comparative analysis.
    Olver JS; Burrows GD; Norman TR
    Hum Psychopharmacol; 2004 Jan; 19(1):9-16. PubMed ID: 14716706
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A double-blind comparison between bupropion XL and venlafaxine XR: sexual functioning, antidepressant efficacy, and tolerability.
    Thase ME; Clayton AH; Haight BR; Thompson AH; Modell JG; Johnston JA
    J Clin Psychopharmacol; 2006 Oct; 26(5):482-8. PubMed ID: 16974189
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined antidepressant treatment: a risk factor for switching in bipolar patients.
    Gabbay V; O'Dowd MA; Asnis GM
    J Clin Psychiatry; 2002 Apr; 63(4):367; author reply 367-8. PubMed ID: 12000212
    [No Abstract]   [Full Text] [Related]  

  • 10. Extended-release venlafaxine in relapse prevention for patients with major depressive disorder.
    Simon JS; Aguiar LM; Kunz NR; Lei D
    J Psychiatr Res; 2004; 38(3):249-57. PubMed ID: 15003430
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bupropion sustained release: a therapeutic overview.
    Davidson JR; Connor KM
    J Clin Psychiatry; 1998; 59 Suppl 4():25-31. PubMed ID: 9554318
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic considerations of antidepressant use in the elderly.
    DeVane CL; Pollock BG
    J Clin Psychiatry; 1999; 60 Suppl 20():38-44. PubMed ID: 10513858
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence of sexual dysfunction among newer antidepressants.
    Clayton AH; Pradko JF; Croft HA; Montano CB; Leadbetter RA; Bolden-Watson C; Bass KI; Donahue RM; Jamerson BD; Metz A
    J Clin Psychiatry; 2002 Apr; 63(4):357-66. PubMed ID: 12000211
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A double-blind study of the efficacy of venlafaxine extended-release, paroxetine, and placebo in the treatment of panic disorder.
    Pollack MH; Lepola U; Koponen H; Simon NM; Worthington JJ; Emilien G; Tzanis E; Salinas E; Whitaker T; Gao B
    Depress Anxiety; 2007; 24(1):1-14. PubMed ID: 16894619
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antidepressant side effects in depression patients treated in a naturalistic setting: a study of bupropion, moclobemide, paroxetine, sertraline, and venlafaxine.
    Vanderkooy JD; Kennedy SH; Bagby RM
    Can J Psychiatry; 2002 Mar; 47(2):174-80. PubMed ID: 11926080
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Venlafaxine extended release versus conventional antidepressants in the remission of depressive disorders after previous antidepressant failure: ARGOS study.
    Baldomero EB; Ubago JG; Cercós CL; Ruiloba JV; Calvo CG; López RP
    Depress Anxiety; 2005; 22(2):68-76. PubMed ID: 16094658
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized, double-blind comparison of duloxetine and venlafaxine in the treatment of patients with major depressive disorder.
    Perahia DG; Pritchett YL; Kajdasz DK; Bauer M; Jain R; Russell JM; Walker DJ; Spencer KA; Froud DM; Raskin J; Thase ME
    J Psychiatr Res; 2008 Jan; 42(1):22-34. PubMed ID: 17445831
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Persistence with once-daily versus twice-daily bupropion for the treatment of depression in a large managed-care population.
    Stang P; Suppapanaya N; Hogue SL; Park D; Rigney U
    Am J Ther; 2007; 14(3):241-6. PubMed ID: 17515697
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combining antidepressant medications: a good idea?
    Rush AJ
    Am J Psychiatry; 2010 Mar; 167(3):241-3. PubMed ID: 20194484
    [No Abstract]   [Full Text] [Related]  

  • 20. Adherence to antidepressant combinations and monotherapy for major depressive disorder: a CO-MED report of measurement-based care.
    Warden D; Trivedi MH; Carmody T; Toups M; Zisook S; Lesser I; Myers A; Kurian KR; Morris D; Rush AJ
    J Psychiatr Pract; 2014 Mar; 20(2):118-32. PubMed ID: 24638046
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.